Jasper Therapeutics reports data from BEACON study of briquilimab

Jasper Therapeutics (JSPR) reported preliminary data from Jasper’s ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU. Substantial reductions in UAS7 were reported, with a mean change from baseline at 8 weeks of -26.6 in the 240mg single-dose cohort and multiple dosing regimens at or above 120mg demonstrating UAS7 changes of more than -25 points. 100% Complete Responses observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks. Clinical responses were observed as early as 1-week post-first dose, and Complete Responses were achieved by patients at each therapeutic dose level, most notably, all patients in the 240mg single-dose cohort maintained Complete Responses through the 8-week time-point. Durability of response was generally dose dependent and reductions in serum tryptase to levels below the lower limit of quantification were observed at multiple dose levels. Briquilimab was well tolerated in the study with a favorable safety profile.